Abstract: Highblood levels of very low density lipoprotein lipids (VLDLs) and glycoprotein acyl (Glyc A) are known to increase risk of diabetes, cardiovascular diseases, inflammations, cognitive impairments, cancers and premature deaths in sedentary persons. The invention determines physical activity thresholds of daily steps and accelerations to reduce plasma concentrations of VLDLs and Glyc A. The method and device is an accelerometer recording and classifying numbers of steps and accelerations and comparing the person's steps and accelerations with those shown to reduce VLDLs and Gly A. The invention is characterized in that if the daily number of accleration maxima exceeds the given en threshold of 2980 steps in the acceleration range 1.3-1.7 g, the person has performed physical activity, typically known to reduce circulating VLDLs and Glyc A.

Abstract: Highblood levels of very low density lipoprotein lipids (VLDLs) and glycoprotein acyl (Glyc A) are known to increase risk of diabetes, cardiovascular diseases, inflammations, cognitive impairments, cancers and premature deaths in sedentary persons. The invention determines physical activity thresholds of daily steps and accelerations to reduce plasma concentrations of VLDLs and Glyc A. The method and device is an accelerometer recording and classifying numbers of steps and accelerations and comparing the person's steps and accelerations with those shown to reduce VLDLs and Gly A. The invention is characterized in that if the daily number of accleration maxima exceeds the given en threshold of 2980 steps in the acceleration range 1.3-1.7 g, the person has performed physical activity, typically known to reduce circulating VLDLs and Glyc A.

Abstract: Discloses are method and device determining threshold values for the volume and intensity of physical activity and the lowest levels of this activity that reduce risk factors in overweight persons who suffer from disorders of sugar and lipid metabolism. The method comprises of registering a person's daily physical activity, comparing it with the measured/predetermined threshold levels and informs the person, if the volume and/or intensity of the physical activity has been sufficient to prevent the effects of disease risk factors. Based on the disclosed methodology, overweight persons having disorders in sugar and lipid metabolism are able to perform physical activity maintaining health and reducing the risk factors. The invention described herein demonstrates a novel opportunity for overweight people having an abnormal blood sugar to use the low intensity physical activity to restrain risk factors related to cardiovascular diseases, diabetes and obesity.

Abstract: Method and device determine the threshold values for the volume and intensity of physical activity or the lowest levels that reduce risk factors in persons who suffer from disorders of sugar and lipid metabolism and are overweight. The method characterized in that the device registers a person's daily physical activity, compares it with the measured threshold levels and informs by its own or outside screen, if the volume and/or intensity of the physical activity has been sufficient to prevent the effects of disease risk factors. Based on this persons, who have disorders in sugar and lipid metabolism are able to perform physical activity maintaining health. The invention described herein demonstrates as a novel observation that even the low intensity physical activity will restrain risk factors related to cardiovascular diseases, diabetes and obesity.

Abstract: An in vivo method of determining activation or inactivation of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems, the method comprising simultaneously detecting the presence or amount of atrial and brain natriuretic peptide prohormones (proANP and proBNP) or fragments thereof in a sample.

Abstract: An in vivo method of determining activation or inactivation of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems, the method comprising simultaneously detecting the presence or amount of atrial and brain natriuretic peptide prohormones (proANP and proBNP) or fragments thereof in a sample.

Abstract: An in vitro method of determining activation or inactivation of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems, the method comprising simultaneously detecting the presence or amount of atrial and brain natriuretic peptide prohormones (proANP and proBNP) or fragments thereof in a sample.

Abstract: A measuring device and a method estimates the quantity and quality of exercises performed having an advantageous impact on cholesterol metabolism. In the method, accelerations exerted on a person during daily exercise performed by the person are continuously recorded by a measuring device including an acceleration transducer. The recorded results are visible in the measuring device or an external device. Based on the received feedback, the person can change the quantity and quality of his/her exercise so that it has an advantageous impact on cholesterol metabolism.

Abstract: The invention deals with the use of a reactive compound in immunological analyses. The compound is ouabain or its analog to which another compound, labeled by radioiodine or by a fluorogen, is coupled. The invention covers also the method to measure ouabain or its analog in plasma to diagnose cardiovascular and endocrine diseases and other harmful conditions.